ZUMA-8: A Phase 1 Study of KTE-X19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy, in Patients With Relapsed/Refractory Chronic Lymphocytic LeukemiaMatthew S. Davids, Javier Pinilla Ibarz, Michael Maris et al.|Blood|2022Cited by 12